System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Studies

Observational Recruiting

NCT05542056 on ClinicalTrials.gov

Urinary Prostaglandin as a Potential Predictive Marker for Thiazide-induced Hyponatremia

Official title: Urinary Prostaglandin as a Potential Predictive Marker for Thiazide-induced Hyponatremia: a Prospective Cohort Study (The PROPHECY Study)

  • Sponsor: University Hospital of Basel
  • Enrollment: 232 (Estimated)
  • Study start: 2022-09-26 (Actual)
  • Primary completion: 2026-07-01 (Estimated)
  • Study completion: 2026-07-01 (Estimated)
  • Allocation: N/a
  • InterventionModel: N/a
  • Masking: None
  • PrimaryPurpose: Other

Brief Summary

Thiazides and thiazide-like diuretics are one of the five major classes of antihypertensive drugs. This study is to investigate whether urinary PGE2 concentration at baseline (prior to thiazide initiation) is associated with the development of TIH within the first four weeks of treatment.

Conditions

  • Thiazide-induced Hyponatremia (TIH)

Intervention / Treatment

  • Other: Data and biosample collection

Primary Outcome Measures

  • Occurrence of hyponatremia (plasma sodium <135 mmol/L) (Within the first four weeks of treatment (at visit 2))
    Occurrence of hyponatremia (plasma sodium \<135 mmol/L)

Countries

Spain, Switzerland

Locations and Investigators

  • Hospital Universitario de Móstoles, Móstoles, Spain (Recruiting)
    • Alberto Fernandez Martinez, Prof. Dr. med.
  • University Hospital Basel, Endocrinology, Diabetes and Metabolism, Basel, Switzerland (Recruiting)
    • Julia Beck, Dr. med.
    • Julia Beck, Dr. med. (Principal Investigator)
    • Sophie Monnerat
    • Thilo Burkard, Dr. med.
    • Michael Mayr, PD Dr. med.
    • Ewout J. Hoorn, Prof. Dr. med.
  • Kantonsspital Baselland, Liestal, Switzerland (Recruiting)
    • Felix Burkhalter Pirovino, Dr. med.
    • Felix Burkhalter Pirovino, Dr. med. (Principal Investigator)
    • Jörg Leuppi, Prof. Dr. med.

Study Officials